首页> 美国卫生研究院文献>other >A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders (AUD)
【2h】

A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders (AUD)

机译:纳曲酮用于减轻患有酒精使用障碍的女性的酒精消耗的系统评价(AUD)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Several clinical trials have evaluated naltrexone as a treatment for alcohol use disorders, but few have focused on women. The aim of this review was to systematically review and summarize the evidence regarding the impact of naltrexone compared to placebo for attenuating alcohol consumption in women with an alcohol use disorder (AUD).A systematic review was conducted using PubMed, Cochrane, Web of Science, CINAHL, and Alcohol Studies Database to identify relevant peer-reviewed randomized controlled trials (RCTs) published between January 1990 and August 2016.Seven published trials have evaluated the impact of naltrexone on drinking outcomes in women distinct from men. 903 alcohol-dependent or heavy drinking women were randomized to receive once daily oral or depot (injectable) naltrexone or placebo with/without behavioral intervention. Two studies examining the quantity of drinks per day observed trends toward reduction in drinking quantity among women who received naltrexone vs. placebo. The 4 studies examining the frequency of drinking had mixed results, with one study showing a trend that favored naltrexone, two showing a trend that favored placebo, and one that showed no difference. Two of the three studies examining time to relapse observed trends that tended to favor naltrexone for time to any drinking and time to heavy drinking among women who received naltrexone vs. placebo.While the growing body of evidence suggests a variety of approaches to treat alcohol use disorders (AUD), the impact of naltrexone to combat AUD in women is understudied. Taken together, the results suggest that naltrexone may lead to modest reductions in quantity of drinking and time to relapse, but not on the frequency of drinking in women. Future research should incorporate sophisticated study designs that examine gender differences and treatment effectiveness among those diagnosed with an AUD and present data separately for men and women.
机译:几项临床试验评估了纳曲酮作为酒精滥用障碍的治疗方法,但很少有人关注女性。这篇综述的目的是系统地回顾和总结有关纳曲酮与安慰剂相比对减少酒精使用障碍(AUD)妇女的饮酒量的影响的证据。使用PubMed,Cochrane,Web of Science, CINAHL和酒精研究数据库来确定1990年1月至2016年8月间发表的相关同行评审随机对照试验(RCT),其中有7项试验评估了纳曲酮对不同于男性的女性饮酒结果的影响。随机将903名酒精依赖或重度饮酒的妇女接受/不接受行为干预的情况下,每天口服一次或口服(可注射的)纳曲酮或安慰剂。两项研究每天饮酒量的研究发现,接受纳曲酮和安慰剂治疗的女性饮酒量呈下降趋势。检验饮酒频率的4项研究结果参差不齐,一项研究表明偏爱纳曲酮的趋势,两项研究表明偏爱安慰剂的趋势,另一项研究无差异。在研究复发时间的三项研究中,有两项研究观察到在接受纳曲酮和安慰剂治疗的女性中,倾向于不饮酒和不饮酒的趋势倾向于纳曲酮。尽管越来越多的证据表明,有多种治疗酒精滥用的方法疾病(AUD)中,纳曲酮对妇女抗击AUD的影响尚未得到充分研究。两者合计,结果表明纳曲酮可导致适度减少饮酒量和复发时间,但不会降低女性饮酒的频率。未来的研究应纳入复杂的研究设计,以检查被诊断患有澳元的人之间的性别差异和治疗效果,并分别提供男女数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号